Detail akcie Assertio Hldgs Rg online

Business Summary: Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Assertio Holdings Inc revenues decreased 5% to $118.7M. Net loss increased 41% to $30.4M. Revenues reflect INDOCIN products segment decrease of 29% to $18.9M, other segment decrease of 33% to $10.7M, Other revenue segment decrease from $2.1M to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$3.40 to -$4.74.